Elmar Kraus
Stock Analyst at DZ Bank
(2.95)
# 1,561
Out of 4,711 analysts
12
Total ratings
80%
Success rate
25.75%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Elmar Kraus
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LLY Eli Lilly | Downgrades: Hold | $820 | $767.76 | +6.80% | 4 | Feb 21, 2024 | |
| GSK GSK | Downgrades: Hold | n/a | $33.60 | - | 1 | Feb 11, 2022 | |
| AZN AstraZeneca | Upgrades: Hold | n/a | $65.35 | - | 1 | Feb 11, 2022 | |
| PFE Pfizer | Upgrades: Buy | $41 | $26.36 | +55.54% | 2 | Feb 4, 2021 | |
| MDT Medtronic | Downgrades: Hold | $92 | $81.03 | +13.54% | 2 | May 14, 2020 | |
| GILD Gilead Sciences | Upgrades: Buy | n/a | $92.57 | - | 2 | Mar 18, 2020 |
Eli Lilly
Feb 21, 2024
Downgrades: Hold
Price Target: $820
Current: $767.76
Upside: +6.80%
GSK
Feb 11, 2022
Downgrades: Hold
Price Target: n/a
Current: $33.60
Upside: -
AstraZeneca
Feb 11, 2022
Upgrades: Hold
Price Target: n/a
Current: $65.35
Upside: -
Pfizer
Feb 4, 2021
Upgrades: Buy
Price Target: $41
Current: $26.36
Upside: +55.54%
Medtronic
May 14, 2020
Downgrades: Hold
Price Target: $92
Current: $81.03
Upside: +13.54%
Gilead Sciences
Mar 18, 2020
Upgrades: Buy
Price Target: n/a
Current: $92.57
Upside: -